Increased Risk of Heart Failure in Type II Diabetes Drugs
The U.S. Food & Drug Administration (FDA) has issued a safety communication related to certain medications used by millions of Americans who suffer from type II diabetes. After evaluating two large clinical studies the FDA has announced new warnings to be added to the labels of Onglyza, Kombiglyze, Nesina, Kazano and Oseni, medications that contain either saxagliptin or alogliptin. The clinical studies showed that the use of the medications may increase the risk of heart failure. Heart failure can result in the heart not being able to pump enough blood to meet the body’s needs.
Symptoms of heart failure can include shortness of breath; trouble breathing when lying down; fatigue; weight gain and swelling in the extremities. If you or a loved one suffers from type II diabetes, has been using Onglyza, Kombiglyze, Nesina, Kazano or Oseni and have suffered heart failure let the lawyers at Wilentz help you. For a free consultation, contact us at 1.855.WILENTZ.